This informative session covers advances in Paroxysmal Nocturnal Hemoglobinuria (PNH), with discussions on clinical and biological aspects. Experts explore various treatment options, including C5 inhibitors and their efficacy in managing PNH. The session highlights key data from clinical trials and real-world applications, focusing on patient outcomes and potential future treatments. Speakers also address the importance of prompt diagnosis and the risks associated with PNH, such as thrombosis and complications from bone marrow failure syndromes.